<table>
<thead>
<tr>
<th>Title</th>
<th>Effect of Cevimeline on Radiation-Induced Salivary Gland Dysfunction and AQP5 in Submandibular Gland in Mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Takakura, K; Takaki, S; Takeda, I; Hanaue, N; Kizu, Y; Tonogi, M; Yamane, GY</td>
</tr>
<tr>
<td>Journal</td>
<td>Bulletin of Tokyo Dental College, 48(2): 47-56</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10130/203">http://hdl.handle.net/10130/203</a></td>
</tr>
</tbody>
</table>
Effect of Cevimeline on Radiation-Induced Salivary Gland Dysfunction and AQP5 in Submandibular Gland in Mice

Katsuhiro Takakura, Sachiko Takaki, Ienaka Takeda*, Nobuyuki Hanaue, Yasuhiro Kizu, Morio Tonogi and Gen-yuki Yamane

Department of Oral Medicine, Oral and Maxillofacial Surgery, Tokyo Dental Collage, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan
* Department of Radiation Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue Edmonton, Alberta T6G 1Z2, Canada

Received 17 January, 2007/Accepted for publication 18 May, 2007

Abstract

The aim of this study was to clarify the effects of the muscarinic receptor agonist, cevimeline, on saliva flow and expression of aquaporin5 (AQP5) in submandibular gland after X-ray irradiation. Using a previously established radiation-induced xerostomia model mouse, saliva flow from at 7 days before irradiation to at 28 days after irradiation was investigated in mice that were treated with cevimeline before or after irradiation. Radiation caused a significant decrease in saliva flow compared with nonirradiated salivary glands. Cevimeline post-treatment also caused a significant decrease in saliva flow. In contrast, cevimeline pre-treatment did not significantly decrease saliva flow. Expression of AQP5 fluorescent intensity and mRNA were also analyzed. Irradiation significantly decreased expression of AQP5 in submandibular gland. However, pre-treatment with cevimeline prevented this decrease in AQP5 expression. These data suggest that pre-treatment with cevimeline prevents radiation-induced xerostomia and radiation-induced decrease in expression of AQP5 in submandibular gland.

Key words: Cevimeline—Aquaporin5—Radiation—Xerostomia—Salivary gland

Introduction

Radiotherapy is one of the most important treatments for oral, head and neck cancers. However, by necessity, the treatment field required for irradiation of cancerous tissue includes areas of normal tissue, and thus is associated with subsequent negative effects. In particular, it has been shown that xerostomia results from decreased saliva flow, and this damage is often irreversible. It remains unclear as to why salivary glands, which have a slow turnover (>60 days), have high radiosensitivity. Additionally, radiation damage leads to immediate salivary gland dysfunction. The mechanism behind radiation-induced xeros-
tomia remains to be elucidated.

Cevimeline is a muscarinic agonist that directly stimulates muscarinic acetylcholine receptors in the salivary gland. Because cevimeline has a long-acting salivagogic effect\(^8\), it is predicated to ameliorate radiation-induced xerostomia. Aquaporins (AQP5s) are membrane proteins forming water channels, and are widely distributed through the organisms. Of the known AQP5s, AQP1, AQP3, AQP4, AQP5 and AQP8 have been identified in mammalian salivary glands\(^1,13,19\). In muscarinic agonist stimulation studies, Ma et al.\(^15\) found that showed no defect in the volume or composition of saliva in AQP5-knockout mice, but did in AQP5-knockout mice. These reports have played an important role in the understanding of AQP5 in saliva flow\(^1,13,15,19\). One study investigated the distribution of AQP3, but the mechanism of this distribution remains to be elucidated\(^1\).

For example, they demonstrated that high epithelial cell membrane water permeability is required for active, near-isosmolar fluid transport. Evidence for the expression of AQP8 in the submandibular glands of rats and mice has been reported, although the localization of AQP8 has yet to be established\(^12,16\).

The present experiment employed irradiation of a xerostomia model mouse irradiated by X-rays to investigate the usefulness of cevimeline in irradiation-induced xerostomia. Both immunofluorescence and qRT-PCR were used to investigate expression of AQP5.

**Materials and Methods**

1. **Animals**

Five-week-old (body weight 25–31.5g) female ICR mice (Clea Japan Inc., Tokyo) were used in all experiments. They were housed in polycarbonate cages under a 12-hour light-dark cycle. Food and water were given *ad libitum*. After a week of acclimatization, the study was started. The study was carried out according to “The guideline for the treatment of experimental animals in Tokyo Dental College” (1823-05).

2. **Experimental group**

Cevimeline was dissolved in saline at 10 mg/kg bw and administered orally with a feeding tube once daily during the experimental periods as follows: 1) from 7 days before to 28 days after irradiation (R\(^\text{PRE}\) group); 2) only 28 days after irradiation (R\(^\text{POST}\) group); 3) 28 days for non-irradiation (CE group).

Vehicle saline (2ml/kg bw) was administered orally with a feeding tube for 35 days to the non-irradiated animals (N group) and irradiated animals (R group), or supplied for without cevimeline administration to the irradiated animals (Fig. 1).

3. **Irradiation**

All mice were treated with cevimeline or vehicle saline orally with a feeding tube 1 hour before irradiation. Irradiation was performed according to the study of Takeda et al.\(^25\). Briefly, all animals were anesthetized with an intraperitoneal injection of 60mg/kg bw pentobarbital sodium. In the R, R\(^\text{PRE}\) and R\(^\text{POST}\) groups, the bilateral submandibular glands were irradiated with a single dose of 15Gy delivered by the X-ray unit.
Salivary Gland Dysfunction after Irradiation

MEVATORON74 DX40 (Toshiba Medical System, Tokyo) at a dose rate of 3 Gy/min.

4. Collection of saliva
Saliva was collected at 7 days before and at 1, 3, 5, 7, 14 and 28 days after irradiation (n = 5). The mice were fasted during the 6 hours before the experiment, but were given access to water. All mice were weighed and anesthetized with an intraperitoneal injection of pentobarbital (50 mg/kg). Ten minutes after pentobarbital injection, pilocarpine (0.5 mg/kg) was injected intraperitoneally to stimulate saliva flow. Saliva was collected from the floor of the mouth with a capillary micropipette during the first 15 minutes after pilocarpine injection, and normalized to total body weight on the day of saliva collection. Mice did not receive cevimeline or normal saline on the day they were stimulated with pilocarpine.

5. Immunofluorescence analysis
After treatment with cevimeline for 10 minutes, submandibular glands were dissociated (n = 3). The tissue specimens were embedded in OCT compound (Tissue-tek, Miles, IN) and frozen in liquid nitrogen. Frozen sections were cut into 4 μm slices. After washing in phosphate buffered saline (3 times for 5 minutes each time), the sections were fixed in cold acetone for 5 min, and then washed. The sections were blocked in 10% fetal bovine serum for 1 hour. The sections were incubated overnight at 4°C with primary antibodies, goat polyclonal anti-AQP5 antibodies (1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), and then washed. Washed sections were incubated in Vectashield (Vector Laboratories, Burlingame, CA). To evaluate the amount of AQP5, tissues showing deposition of fluorescence to FITC (The Jackson Laboratory, Bar Harbor, ME). Sections were mounted in Vectashield. The sequence of the primer to amplify mouse AQP5 was designed as follows: forward primer, 5’-GCC TTATCCATTGGGCTTGC-3’; reverse primer, 5’-CCCAGAAGACCCAGTGAGAG-3’. The product size amplified with this primer set was 138 bp. The sequence of the primer to amplify mouse actin was designed as follows: forward primer, 5’-CATTGCTGACAGGATGCAGAA-3’; reverse primer, 5’-GCTGATCCATCTGCTGAGA-3’. The product size amplified with this primer set was 150 bp. These primers were designed using Primer Express software (Applied Biosystems). PCR conditions included an initial incubation at 95°C for 10 min followed by 40 cycles comprising 15 s at 95°C–60 s at 60°C. The relative quantities of different mRNA transcripts were calculated after normalization of the data against the level of actin using the comparative CT method. Expression was calculated as relative to that of day 1 of group N, defined as 1.

Statistical Analysis
The experiments were repeated two times. Values given are the means of all measure-
Fig. 2 Effects of cevimeline on saliva flow rate during first 15 min after pilocarpine (0.5 mg/kg) stimulation. Mice saliva flow in non-irradiated (N), irradiated (R), irradiated + pre-treatment with cevimeline (R PRE), and irradiated + post-treatment with cevimeline (R POST) groups. Five mice in each group were analyzed. Values represent mean ± SD. *p<0.05, **p<0.01 compared with group N.

1. Effects of cevimeline on saliva flow

Figure 2 shows the effects of cevimeline on saliva flow rate (n = 5). In the R group, irradiation significantly decreased saliva flow rate at 1, 3, 5, 7, 14 and 28 days (2.85 ± 0.42, 2.64 ± 0.46, 2.57 ± 0.97, 2.68 ± 0.74, 2.66 ± 0.74, 2.68 ± 1.08 μl/g) compared with the N group (4.68 ± 0.57, 5.29 ± 0.72, 5.10 ± 0.95, 5.26 ± 0.74, 5.22 ± 1.26, 5.00 ± 0.59 μl/g) (p<0.01). In the R POST group, saliva flow rate was also significantly decreased at 1, 3, 5, 7, 14 and 28 days (2.65 ± 0.20, 2.98 ± 0.73, 3.40 ± 1.12, 3.47 ± 0.32, 3.29 ± 0.61, 3.67 ± 0.92 μl/g) compared with the N group (p<0.01). Although a slight recovery in saliva flow rate was observed at 7 days after irradiation compared with in the R group, none of these increases were significant compared with in the R group (p<0.05). In contrast, in the R PRE group, saliva flow rate showed no significant decrease at 1, 3, 5, 7, 14 or 28 days (3.78 ± 1.40, 4.46 ± 1.26, 4.51 ± 0.83, 4.33 ± 0.81, 4.23 ± 0.93, 4.40 ± 1.46 μl/g) compared with the N group (p<0.05). A recovery in saliva flow rate was seen at 3 days after irradiation compared with in the R group. These increases were significant compared with R group during days 1–28 (p<0.01).

2. Immunofluorescence

An example of distribution of AQP5 in mouse submandibular gland by immunofluorescence with affinity-purified antibodies to mouse AQP5 is shown in Fig. 3. AQP5 is normally expressed in the apical plasma membrane of acinar (Fig. 3A) and duct cells (Fig. 3B). In this study, comparative experiments were performed in acinar cells. Immunofluorescence detection of AQP5 protein in mouse submandibular glands in the R, R PRE and R POST groups at 0, 1, 7, 14 and 28 days after irradiation are shown in Fig. 4A (n = 3). Immunolocalization of AQP5 protein, which was analyzed by fluorescent intensity with the Color Image Analyzer, is shown in Fig. 4B. In the R group, fluorescence intensity in the acinar cells was significantly decreased at 1, 3, 5, 7, 14 and 28 days (35.72 ± 9.36, 33.72 ± 8.04, 31.42 ± 6.68, 30.82 ± 8.5, 30.56 ± 8.43, 30.64 ± 8.43) compared with the N group (70.62 ± 12.5,
In the R+POST group, fluorescence intensity in the acinar cells was significantly decreased at 1, 3, 5, 7, 14 and 28 days (35.42 ± 10.67, 36.99 ± 10.22, 41.11 ± 9.54, 47.04 ± 13.04, 54.31 ± 11.79, 59.89 ± 17.14) compared with the N group (p<0.01). However recoveries were observed at 3 days after irradiation compared with the R group. In contrast, in the R+PRE group, fluorescence intensity in the acinar cells was increased significantly at 0 day (96.01 ± 17.25) compared with the N group (70.69 ± 10.33) (p<0.01). However, fluorescence intensity decreased significantly after 3, 5 and 7 days (55.21 ± 14.05, 52.65 ± 10.71, 57.93 ± 17.82) (p<0.01), increasing again at 7 days compared with the R group. After 14 days, fluorescence intensity showed no significant decrease (62.19 ± 12.26) compared with the N group (p<0.05), and recoveries were observed compared with the R group.

In the CE group, fluorescent intensity at 7, 14, 21 and 28 days after treatment is shown in Fig. 5A. Immunolocalization of AQP5 protein, which was analyzed via fluorescent intensity with the Color Image Analyzer, is shown in Fig. 5B. Fluorescence intensity showed a significant increase in the acinar cells at 7, 14, 21 and 28 days (96.48 ± 17.25, 96.31 ± 13.19, 105.36 ± 21.46, 105.85 ± 17.00) compared with the N group (p<0.01).

3. Expression of AQP5 mRNA

Figure 6 shows the expression of AQP5 mRNA in mouse submandibular glands by qRT-PCR. Figure 6A shows the CE and N groups at 0, 7, 14, 21 and 28 days after treatment with cevimeline, and Fig. 6B shows the R, PRE and POST groups at 7, 1, 7, 14 and 28 days after irradiation.

Expression of AQP5 mRNA was highest at 7 days in the CE group. However, expression of AQP5 mRNA was slightly higher in the CE group than in the N group. In the R and R+POST groups, expression of AQP5 mRNA was lower than in the N group at −7, 1, 7, 14 and 28 days, but not significantly so. In the R+POST group, slight recoveries were observed at 7 days after irradiation. In contrast, in the R+PRE group, expression of AQP5 mRNA at 1 day (1.78 ± 0.23) was significantly higher than that in the N group (0.99 ± 0.38). Expression of AQP5 mRNA in the R+PRE group was similar to that in the N group during days 14–28. In addition, in the CE group, expression of AQP5 mRNA at 7 and 14 days (1.82 ± 0.36, 1.51 ± 0.20) was significantly higher than that in the N group (0.99 ± 0.38, 1.06 ± 0.21). In all groups, RT-PCR products of AQP5 and actin were obtained with a single band (data not shown).

Discussion

Irradiation did not decrease body weight in any group. In contrast, in previous studies, irradiated animals have been shown to display a reduction in body weight. These changes were probably caused by changes in the amount of food and water intake caused by anesthesia and irradiation. In this study, the oral cavity was not included in the X-ray field, which may have minimized the side effects (ulcer, mucositis etc.) of irradiation.

We observed that irradiation significantly decreased the saliva flow rate. Post-treatment with cevimeline also significantly decreased the saliva flow rate, although slight recoveries were observed at 3 days after irradiation. Pre-treatment did not significantly decrease the saliva flow rate. These data suggest that salivary flow is significantly decreased by irradiation. However, pre-treatment prevents irradiation-induced decrease in saliva flow rate.

Coppes et al. reported that pre-treatment with muscarinic acetylcholine receptor and alpha-adrenoceptor agonists protected salivary glands from radiation damage. Moreover, they suggested that indication of protection by muscarinic acetylcholine receptor and alpha-adrenoceptor agonists was mediated by PLC/PIP2 second messenger pathways. Tapp and Trowell suggested that pre-treatment with the muscarinic acetylcholine receptor agonist pilocarpine caused the formation of watery vacuoles. They hypothesized that this vacuole...
Fig. 3

Fig. 4

Fig. 5
formation was the main prophylactic mechanism of muscarinic acetylcholine receptor agonists against irradiation damage.

Previous reports have shown that in the early stage, there is no correlation between apoptosis and salivary gland dysfunction. Therefore, radiation-induced apoptosis alone cannot explain the mechanisms of salivary gland dysfunction. Moreover, free radicals are also important factors for radiation. It is known that hydroxyl radicals indirectly injure DNA. An earlier study showed the pathway by which nitric oxide affects the pathogenesis of radiation-induced salivary gland dysfunction.

Irradiation decreased AQP5 fluorescence intensity and expression of AQP5 mRNA in the submandibular glands. Post-treatment with cevimeline also decreased AQP5 fluorescence intensity and expression of AQP5 mRNA, although slight recoveries were observed 3–7 days after irradiation. In contrast, pre-treatment increased AQP5 fluorescence intensity and expression of AQP5 mRNA in submandibular glands at 7 days compared with non-irradiated glands. Li et al. reported that irradiation decreased AQP5 significantly in rat submandibular gland. Our data are consistent with their results. Moreover, they also reported that AQP5 was possibly more radiosensitive than other proteins. Our data suggest that irradiation significantly decreases AQP5 in submandibular glands and that AQP5 is essential in saliva flow. Using immunofluorescence analysis and qRT-PCR analysis, we clarified that daily treatment with Cevimeline increased AQP5 expression. This suggests that pre-treatment prevents radiation-induced salivary gland dysfunction.

Previous studies have proposed that radiation-induced dysfunction such as loss of AQP5 and other membrane fusion proteins in acinar cells may cause dysfunction. In addition, the higher radiosensitivity of AQP5 compared with other proteins has also been reported. However, these studies did not investigate the biological activity of AQP5. AQP5 localizes in lipid raft and induced transport to the apical plasma membrane in interlobular duct cells of rat parotid glands by activation of M3 muscarinic acetylcholine receptors. Recent studies have demonstrated that a defect AQP5 transport might contribute to decreased lacrimation and saliva flow in patients with Sjögren’s syndrome. Although a senescent xerostomia rat model showed normal transport of AQP5, a streptozotocin-induced diabetic xerostomia rat model revealed disordered trafficking. The translocation of AQP5 by cevimeline is mediated by elevation of intracellular Ca²⁺ concentrations. Radiation impairs mobilization of Ca²⁺ from intracellular Ca²⁺ stores (such as endoplasmic reticulum). It is possible that radiation-induced disorders in mobilization of Ca²⁺ might impair transport of AQP5. Therefore, AQP5 trafficking must be investigated in future studies.

Clinically, saliva flow rate decreases during the first week of radiation with a fractionation protocol of Gy/dose 1 day. Therefore, we cannot rule out the possibility of regulation of

---

**Fig. 3** Distribution of AQP5 in submandibular gland

Distribution of AQP5 in submandibular gland in acinar cells (A) and duct cells (B) by immunofluorescence with affinity-purified antibodies to mouse AQP5. Scale bar = 20 μm.

**Fig. 4** Immunofluorescence detection of AQP5 and expression of AQP5 analyzed by fluorescent intensity

Immunofluorescence detection of AQP5 in mouse submandibular glands of (A) irradiated (R), irradiated + pre-treatment with cevimeline (R + PRE), and irradiated + post-treatment with cevimeline (R + POST) groups, at 7, 0, 1, 3, 5, 7, 14, 21 and 28 days after irradiation. Values represent mean ± SD. *p < 0.05, **p < 0.01 compared with group N. (n = 3)

**Fig. 5** Immunofluorescence detection of AQP5 and expression of AQP5 analyzed by fluorescent intensity

Immunofluorescence detection of AQP5 in mouse submandibular glands of (A) non-irradiated + treatment with cevimeline (CE) groups and (B) Twenty randomly selected sites (0.016 mm²) on apical plasma membrane in acinar cells were analyzed. Non-irradiated (N), irradiated (R), irradiated + pre-treatment with cevimeline (R + PRE), and irradiated + post-treatment with cevimeline (R + POST) groups, at 7, 14, 21 and 28 days after treatment with cevimeline. Values represent mean ± SD. *p < 0.05, **p < 0.01 compared with group N. (n = 3).
AQP5 expression. In the epithelial cells of the lung, it has been demonstrated that AQP5 transcription is regulated by cyclic AMP/protein kinase A (PKA) pathways. It is possible that cevimeline causes activation of cyclic AMP-dependent PKA pathways. In fact, other muscarinic receptor agonists, carbachol and isoproterenol, increase saliva flow mediated through cyclic AMP pathways. In contrast to AQP5, it has been demonstrated that signal transduction through protein kinase C (PKC) plays an important role in the expression of AQP4 and AQP9. More recently, it has been demonstrated that radiation caused a significant decrease in AQP5 expression, with reduction in AQP1 and Na+/K+-ATPase proteins in submandibular gland.

In conclusion, pre-treatment with cevimeline prevented radiation-induced salivary gland dysfunction. Furthermore, cevimeline
pre-treatment was more effective than post-treatment. AQP5 may play an important role in radiation-induced salivary dysfunction. Protection of AQP5 may offer a therapeutic strategy for this clinically severe side effect of radiation therapy.

Acknowledgements

We thank Dr. Yutaka Aoyagi for helpful suggestions with respect to the manuscript; and Hirotschi Horita for excellent assistance.

References


Reprint requests to:
Dr. Sachiko Takaki
Department of Oral Medicine,
Oral and Maxillofacial Surgery,
Tokyo Dental College,
5-11-13 Sugano, Ichikawa,
Chiba 272-8513, Japan
E-mail: takaki@tdc.ac.jp